Journal
NATURE MEDICINE
Volume 26, Issue 9, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41591-020-0998-x
Keywords
-
Funding
- Defense Advanced Research Projects Agency (DARPA) [HR0011-18-2-0001]
- NIH [T32 AI007151, 75N93019C00074, 75N93019C00062, 1S10RR028106-01A1, T32 AI095202]
- Dolly Parton COVID-19 Research Fund at Vanderbilt
- National Center for Advancing Translational Sciences [2 UL1 TR000445-06]
- Helen Hay Whitney Foundation postdoctoral fellowship
- Burroughs Wellcome Fund Postdoctoral Enrichment Program Award
- 2019 Future Insight Prize from Merck KGaA
Ask authors/readers for more resources
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date(1,2). In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms. A platform for rapid antibody discovery enabled the isolation of hundreds of human monoclonal antibodies against SARS-CoV-2 and the prioritization of potent antibody candidates for clinical trials in patients with COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available